本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
审批码：TML0031465，有效期为2024-09-20至2025-09-19，资料过期，视同作废
内容策划：方程
项目审核：于轩
题图来源：图虫创意
参考文献：
[1]陈然, 江昌, 马丽, 等. EGFR 突变 NSCLC 患者 TKIs 耐药后 ICIs 治疗进展 [J]. 中国肺癌杂志. 2022; 25(8): 601-608.
[2]Aboubakar Nana F, Ocak S. Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Pharmaceutics. 2021 Sep 15;13(9):1478.
[3] 李咏生, 孙建国, 李梦侠, 等. 第三代 EGFR-TKI 耐药后诊疗策略专家共识 [J]. 中华肺部疾病杂志（电子版）. 2023; 16(2): 145-155.
[4] 单丽芳, 姜俊玲, 张越雄, 等. BRAF V600E 阳性突变晚期非小细胞肺癌患者治疗策略分析及药学监护 [J]. 中国现代应用药学, 39(9): 1208-1213.
[5]Minari R, Bordi P, La Monica S, et al. Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in a patient with EGFR-mutated NSCLC[J]. J Thorac Oncol, 2018, 13(6): E89-E91.
[6]Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737.
[7]NCCN. Non-Small Cell Lung Cancer. Version 6. 2024.
[8] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南 2024[M]. 北京: 人民卫生出版社, 2023.
[9]Zeng R, Luo LF, Sun XW, et al. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature[J]. Cancer Drug Resist. 2021 Dec 1;4(4):1019-1027. doi: 10.20517/cdr.2021.98. eCollection 2021.
[10] 中国抗癌协会肺癌专业委员会. 中国晚期非小细胞肺癌 BRAF 突变诊疗专家共识 [J]. 中华肿瘤杂志, 2023, 45(4):279-290.
[11]C Weng, K Tang, S Jin, et al. Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC. 2023 ESMO ASIA. 560P.
[12]Liu D, Ding K, Yin K, et al. A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC[J]. Sci Rep. 2024 Sep 1;14(1):20302.